The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

New drugs for Rheumatoid arthritis

류마티스 관절염의 새로 개발된 치료제

Seo, Young-Il
서영일

  • Published : 20090100
⟨ Previous Next ⟩

Abstract

Since the late 1990s, based on scientific advancement and biotechnological improvement, many effective drugs such as leflunomide and biologic agents for rheumatoid arthritis (RA) have been developed. These include TNF-${\alpha}$ inhibitors such as etanercept, infliximab, and adalimumab, a peripheral B-cell depleting agent such as rituximab, CTLA-4 Ig such as abatacept, and IL-1 receptor antagonist such as anakira. These new agents have provided good efficacy in the treatment of patents with severe or refractory rheumatoid arthritis and have provided retardation or prevention of radiographic progression or joint destruction despite some side effects such as tuberculosis, infection, malignancies. In this review, new therapeutic alternatives would be given, and chances for more improved outcomes in the care of patients with rheumatoid arthritis provided.

Keywords

References

  1. Genovese MC. Treatment of rheumatoid arthritis. In: Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent JS, eds. Kelley's textbook of rheumatology. 8th ed. p.1119-1143, Philadelphia, Sounders, 2009
  2. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with lefluomide slows radiographic progression of rheumatoid arthritis: Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Study Investigation Group. Arthritis Rheum 43:495-505, 2000 https://doi.org/10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U
  3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916, 2001 https://doi.org/10.1056/NEJM200103223441207
  4. van der Heijede D, Landewe R, Klareskog L, Rodriguez-Valverde V, Settas L, Pedersen R, Fatenejad S. Presentation and analysis of data on radiologic outcome in clinical trials: Experience from the TEMPO study. Arthritis Rheum 52: 49-60, 2005 https://doi.org/10.1002/art.20775
  5. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563, 1998 https://doi.org/10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
  6. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who hand not hand previous methotrexate treatment. Arthritis Rheum 54:26-37, 2006 https://doi.org/10.1002/art.21519
  7. Robinson WH, Genoverse MC, Moreland LW: Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44:1977-1983, 2001 https://doi.org/10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6
  8. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. Demyelination occurring during anti-tumor necrosis factor alpha therapy for imflammatory arthritides. Arthritis Rheum 44:2862-2869, 2001 https://doi.org/10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W
  9. Cohen SB, Emery P, Greenwald MW, Douqados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of multicenter, randomized, double blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793-2806, 2006 https://doi.org/10.1002/art.22025
  10. Kremer JM, Westhovens R, Leon M, Di Giorgeio E, Alten R, Steinfeld S, Russell A, Dougados M. Emery P, Nuamah IF, Williams GR, Becker JC, Gagerty DT, Moreland LW. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907-1915, 2003 https://doi.org/10.1056/NEJMoa035075
  11. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge Z, Becker JC, Westhovens R. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized tral. Ann Intern Med 144:865-876, 2006 https://doi.org/10.7326/0003-4819-144-12-200606200-00003
  12. Cohen S, hurd E, Cush J, Schiff M, Weinblott ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D. Treatment of rheumatoid arthritis with anakira, a remomninat human interleukin-R receptor antiagonist, in combination with methotrexate: result of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614-624, 2002 https://doi.org/10.1002/art.10141